[1]徐珂 礼兆悦 熊杰 班小芳 涂应锋.残余心血管风险与冠状动脉支架失败关系的研究进展[J].心血管病学进展,2023,(11):961.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.001]
　XU Ke,LI Zhaoyue,XIONG Jie,et al.The Relationship Between Residual Cardiovascular Risk and Coronary Stent Failure[J].Advances in Cardiovascular Diseases,2023,(11):961.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.001]
点击复制

残余心血管风险与冠状动脉支架失败关系的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年11期
页码:
961
栏目:
综述
出版日期:
2023-11-25

文章信息/Info

Title:
The Relationship Between Residual Cardiovascular Risk and Coronary Stent Failure
作者:
徐珂1 礼兆悦 1 熊杰 2 班小芳 2 涂应锋 1
(1.哈尔滨医科大学附属第一医院心内科,黑龙江 哈尔滨 150007;2.哈尔滨医科大学附属第二医院心内科,黑龙江 哈尔滨 150081)
Author(s):
XU Ke1; LI Zhaoyue1; XIONG Jie2; BAN Xiaofang2; TU Yingfeng1
(1.Department of Cardiology,The First Affiliated Hospital of Harbin Medical University,Harbin 150007,Heilongjiang,China; 2.Department of Cardiology,The Second Affiliated Hospital of Harbin Medical University,Harbin 150081,Heilongjiang,China)
关键词:
残余心血管风险; 支架内再狭窄; 极晚期支架内血栓; 支架失败; 经皮冠状动脉介入治疗
Keywords:
Residual cardiovascular risk ; In-stent restenosis; Very late stent thrombosis; Stent failure; Percutaneous coronary intervention
DOI:
10.16806/j.cnki.issn.1004-3934.2023.11.001
摘要:
动脉粥样硬化性心血管疾病（ASCVD）是全球人类致死致残的首位病因。目前诸多研究已对血脂、血压及生活方式等传统心血管危险因素展开了深入的研究并取得跨越式进展，尽管传统危险因素已被全面普及且有效防治，但可能导致患者再发不良心血管事件的残余心血管风险尚有待充分研究。经皮冠状动脉介入治疗是ASCVD治疗的一大基石，但与之相关的一系列并发症不可小觑，可导致患者远期生存率下降。如何使ASCVD患者在治疗后获得更好的预后一直是心血管领域研究的热点、重点和难点。现系统总结了残余心血管风险与冠状动脉支架失败的联系，旨在为支架植入患者远期预后及再发事件的防治提供新思路。
Abstract:
Atherosclerotic cardiovascular disease(ASCVD) is the leading cause of death and disability in the worldwide. At present,the research of traditional cardiovascular risk factors including blood lipid,blood pressure and lifestyle have been studied in depth and made great strides. Although traditional risk factors have been fully popularized and effectively prevented,the residual cardiovascular risk that may lead to recurrent adverse cardiovascular events in some patients remains to be fully studied. Percutaneous coronary intervention is the cornerstone therapy for ASCVD,but its related complications should not be underestimated,which leads to a decrease of the long-term survival rate for patients. How to make ASCVD patients get a better prognosis after treatment has always been a hot and difficult point of research in the cardiovascular field. This review systematically summarizes the relationship between residual cardiovascular risk and coronary stent failure,aiming to provide new ideas for the long-term prognosis and prevention of recurrent events in patients with stent implantation.

参考文献/References:

[1] 中国心血管健康与疾病报告编写组,胡盛寿. 中国心血管健康与疾病报告2021概要[J].中国循环杂志,2022,37(6):553-578.

[2] Wang X,Wen D,Chen Y,et al. PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases:a Bayesian network meta-analysis[J]. Cardiovasc Diabetol,2022,21(1):107.

[3] Gragnano F,Calabro P. Role of dual lipid-lowering therapy in coronary atherosclerosis regression:evidence from recent studies[J]. Atherosclerosis,2018,269:219-228.

[4] Hoogeveen RC,Ballantyne CM. Residual cardiovascular risk at low LDL:remnants,lipoprotein(a),and inflammation[J]. Clin Chem,2021,67(1):143-153.

[5] Torrado J,Buckley L,Duran A,et al. Restenosis,stent thrombosis,and bleeding complications:navigating between Scylla and Charybdis[J]. J Am Coll Cardiol,2018,71(15):1676-1695.

[6] Liu HH,Guo YL,Zhu CG,et al. Synergistic effect of the commonest residual risk factors,remnant cholesterol,lipoprotein(a),and inflammation,on prognosis of statin-treated patients with chronic coronary syndrome[J]. J Transl Med,2022,20(1):243.

[7] Dhindsa DS,Sandesara PB,Shapiro MD,et al. The evolving understanding and approach to residual cardiovascular risk management[J]. Front Cardiovasc Med,2020,7:88.

[8] Varbo A,Nordestgaard BG. Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction[J]. Eur Heart J,2021,42(47):4833-4843.

[9] Doi T,Langsted A,Nordestgaard BG. Elevated remnant cholesterol reclassifies risk of ischemic heart disease and myocardial infarction[J]. J Am Coll Cardiol,2022,79(24):2383-2397.

[10] Qin Z,Zhou K,Li YP,et al. Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention:a single-centre observational cohort study[J]. Cardiovasc Diabetol,2019,18(1):11.

[11] Xu X,Pandit RU,Han L,et al. Remnant lipoprotein cholesterol independently associates with in-stent restenosis after drug-eluting stenting for coronary artery disease[J]. Angiology,2019,70(9):853-859.

[12] Ridker PM,Everett BM,Thuren T,et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med,2017,377(12):1119-1131.

[13] Ridker PM. Clinician’s guide to reducing inflammation to reduce atherothrombotic risk:JACC review topic of the week[J]. J Am Coll Cardiol,2018,72(25):3320-3331.

[14] Ajala ON,Everett BM. Targeting inflammation to reduce residual cardiovascular risk[J]. Curr Atheroscler Rep,2020,22(11):66.

[15] Bohula EA,Giugliano RP,Leiter LA,et al. Inflammatory and cholesterol risk in the fourier trial[J]. Circulation,2018,138(2):131-140.

[16] Pradhan AD,Aday AW,Rose LM,et al. Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy[J]. Circulation,2018,138(2):141-149.

[17] Nagano Y,Otake H,Toba T,et al. Impaired cholesterol-uptake capacity of HDL might promote target-lesion revascularization by inducing neoatherosclerosis after stent implantation[J]. J Am Heart Assoc,2019,8(9):e11975.

[18] Kuroda M,Otake H,Shinke T,et al. The impact of in-stent neoatherosclerosis on long-term clinical outcomes:an observational study from the Kobe University Hospital optical coherence tomography registry[J]. EuroIntervention,2016,12(11):e1366-e1374.

[19] Kalkman DN,Aquino M,Claessen BE,et al. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions[J]. Eur Heart J,2018,39(46):4101-4108.

[20] Shah NP,Pajidipati NJ,McGarrah RW,et al. Lipoprotein (a): an update on a marker of residual risk and associated clinical manifestations[J]. Am J Cardiol,2020,126:94-102.

[21] O’Donoghue ML,Fazio S,Giugliano RP,et al. Lipoprotein(a), PCSK9 inhibition,and cardiovascular risk[J]. Circulation,2019,139(12):1483-1492.

[22] Yoon YH,Ahn JM,Kang DY,et al. Association of lipoprotein(a) with recurrent ischemic events following percutaneous coronary intervention[J]. JACC Cardiovasc Interv,2021,14(18):2059-2068.

[23] Xue Y,Jian S,Zhou W,et al. Associations of lipoprotein(a) with coronary atherosclerotic burden and all-cause mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention[J]. Front Cardiovasc Med,2021,8:638679.

[24] Liu HH,Cao YX,Jin JL,et al. Predicting cardiovascular outcomes by baseline lipoprotein(a) concentrations:a large cohort and long-term follow-up study on real-world patients receiving percutaneous coronary intervention[J]. J Am Heart Assoc,2020,9(3):e14581.

[25] Reiner Z. Hypertriglyceridaemia and risk of coronary artery disease[J]. Nat Rev Cardiol,2017,14(7):401-411.

[26] Ganda OP,Bhatt DL,Mason RP,et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management[J]. J Am Coll Cardiol,2018,72(3):330-343.

[27] Raposeiras-Roubin S,Rossello X,Oliva B,et al. Triglycerides and residual atherosclerotic risk[J]. J Am Coll Cardiol,2021,77(24):3031-3041.

[28] Zhu Y,Liu K,Chen M,et al. Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents[J]. Cardiovasc Diabetol,2021,20(1):137.

[29] Yamaji K,Inoue K,Nakahashi T,et al. Bare metal stent thrombosis and in-stent neoatherosclerosis[J]. Circ Cardiovasc Interv,2012,5(1):47-54.

[30] Morton J,Bao S,Vanags LZ,et al. Strikingly different atheroprotective effects of apolipoprotein A-I in early- versus late-stage atherosclerosis[J]. JACC Basic Transl Sci,2018,3(2):187-199.

[31] Vanags LZ,Tan J,Galougahi KK,et al. Apolipoprotein A-I reduces in-stent restenosis and platelet activation and alters neointimal cellular phenotype[J]. JACC Basic Transl Sci,2018,3(2):200-209.

[32] Wu BJ,Li Y,Ong KL,et al. Reduction of in-stent restenosis by cholesteryl ester transfer protein inhibition[J]. Arterioscler Thromb Vasc Biol,2017,37(12):2333-2341.

[33] Vanags LZ,Tan J,Santos M,et al. Plasma activated coating immobilizes apolipoprotein A-I to stainless steel surfaces in its bioactive form and enhances biocompatibility[J]. Nanomedicine,2017,13(7):2141-2150.

[34] Chai D,Yang X,Wang A,et al. Usefulness of platelet distribution width and fibrinogen in predicting in-stent restenosis with stable angina and type 2 patients with diabetes mellitus[J]. Front Cardiovasc Med,2022,9:710804.

[35] Yuan D,Jiang P,Zhu P,et al. Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention:5-year findings from a large cohort study[J]. Cardiovasc Diabetol,2021,20(1):143.

[36] Jayachandran M,Qu S. Harnessing hyperuricemia to atherosclerosis and understanding its mechanistic dependence[J]. Med Res Rev,2021,41(1):616-629.

[37] Wang JL,Qin Z,Wang ZJ,et al. New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent[J]. J Geriatr Cardiol,2018,15(2):137-145.

[38] Tscharre M,Herman R,Rohla M,et al. Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention[J]. Atherosclrosis,2018,270:173-179.

相似文献/References:

[1]刘丹丹 李茜楠 王腾玉 田野.锁骨下动脉狭窄的诊治[J].心血管病学进展,2019,(5):786.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.030]
　LIU Dandan,LI Qiannan,WAND Tengyu,et al.Diagnosis and Treatment of Subclavian Artery Stenosis[J].Advances in Cardiovascular Diseases,2019,(11):786.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.030]
[2]马越 宋雷 乔树宾.腔内影像学在冠状动脉支架内再狭窄中应用的研究进展[J].心血管病学进展,2021,(3):202.[doi:10.16806/j.cnki.issn.1004-3934.20.03.003]
　MA Yue,SONG Lei,QIAO Shubin.Application of Intravascular Imaging in Coronary Artery In-stent Restenosis[J].Advances in Cardiovascular Diseases,2021,(11):202.[doi:10.16806/j.cnki.issn.1004-3934.20.03.003]
[3]张爽 吴娜琼.腔内影像学在冠状动脉支架内再狭窄诊治应用中的研究进展[J].心血管病学进展,2022,(5):389.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.002]
　ZHANG Shuang,WU Na qiong.Application of Intravascular Imaging in Diagnosis and Treatment of Coronary In-Stent Restenosis[J].Advances in Cardiovascular Diseases,2022,(11):389.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.002]
[4]袁晓航 冯欢欢 高磊.复发性支架内再狭窄的研究进展[J].心血管病学进展,2022,(8):677.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.002]
　YUAN Xiaohang FENG Huanhuan GAO Lei.Recurrent In-Stent Restenosis[J].Advances in Cardiovascular Diseases,2022,(11):677.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.002]

更新日期/Last Update: 2023-12-13